Longboard Pharmaceuticals Q2 2024 GAAP EPS $(0.56) Misses $(0.45) Estimate
Portfolio Pulse from Benzinga Newsdesk
Longboard Pharmaceuticals (NASDAQ:LBPH) reported a Q2 2024 GAAP EPS of $(0.56), missing the analyst consensus estimate of $(0.45) by 24.44%. This represents a 13.85% improvement over the $(0.65) loss per share from the same period last year.
August 01, 2024 | 8:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Longboard Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.56), missing the analyst consensus estimate of $(0.45) by 24.44%. Despite the miss, the loss per share improved by 13.85% compared to the same period last year.
The significant miss on the EPS estimate is likely to negatively impact the stock price in the short term. However, the year-over-year improvement in losses may provide some support.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100